Risperidone blocks the dopamine D2 receptor on the pituitary lactotroph, so Cabergoline cannot act there — the effect of Cabergoline is reduced or lost.
Cabergoline is an agonist at the dopamine D2 receptor on the pituitary lactotroph: it binds and switches the receptor on. Risperidone is an antagonist at the same site and switches nothing on. With both present they compete for the same pocket, and whichever is there in greater effective concentration decides what the receptor does.
Given together they work against whatever each was started for. If both are genuinely needed, expect less of Cabergoline’s effect than its dose would suggest.
This is a pharmacodynamic interaction. Neither drug changes the other’s concentration, so a level, an AUC estimate or a genotype looks entirely normal while the clinical effect is blunted.
The direction can be the useful one. The same opposition is what makes a reversal agent, an antidote or a planned antagonist work.
The endpoint they are fighting over is prolactin. Risperidone raises it by blocking D2 receptors on the pituitary lactotroph, which releases prolactin from its normal dopaminergic brake; cabergoline lowers it by stimulating the same receptors. Given together the level reflects whichever is winning, and cabergoline may not correct an antipsychotic-driven hyperprolactinemia at a dose that would correct a prolactinoma.



The ring marks the peg each drug wears for this receptor — the same cross-illumination Interact! draws when the two are put side by side.

